Table 1.
Studies included in this comparative analysis
| Author | Year | Drug | Study design | Treatment duration (days) | Urticaria subtype | n | Parameter of efficacy | Reference numbers |
|---|---|---|---|---|---|---|---|---|
| Finn | 1999 | Fexofenadine | DB,PC | 28 | CSU/CIU | 439 | MPS | 17 |
| Nelson | 2000 | Fexofenadine | R,DB,PC | 28 | CSU/CIU | 418 | MPS | 18 |
| Giménez-Arnau | 2007 | Rupatadine | R,DB,PC | 28 | CSU/CIU | 329 | MPS | 19 |
| Dubertret | 2007 | Rupatadine | R,DB,PC | 28 | CSU/CIU | 277 | MPS | 20 |
| Siebenhaar | 2009 | Desloratadine | R,DB,PC | 7 | ACU | 30 | % SF | 21 |
| Staevska | 2010 | Desloratadine | DB,PC | 28 | CSU/CIU | 40 | % SF | 22 |
| Staevska | 2010 | Levocetirizine | DB,PC | 28 | CSU/CIU | 40 | % SF | 22 |
| Krause | 2013 | Bilastine | R,DB,PC | 7 | ACU | 20 | % SF | 23 |
DB double-blind, PC placebo-controlled, R randomized.
CSU chronic spontaneous urticaria, CIU chronic idiopathic urticaria, ACU acquired cold urticaria.
MPS mean pruritus score, % SF percentage of symptom-free patients.